Retatrutide 0.5mg

Retatrutide is an investigational triple agonist drug targeting the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors, currently being developed by Eli Lilly for the treatment of obesity and type 2 diabetes.
Key Points About Retatrutide 1mg:

Mechanism of Action:

Simultaneously activates GIP, GLP-1, and glucagon receptors, which may enhance weight loss and glycemic control more effectively than single or dual agonists (like semaglutide or tirzepatide).

GIP & GLP-1 improve insulin secretion and reduce appetite.

Glucagon may increase energy expenditure by promoting fat metabolism.

Clinical Trials (Phase 2 Data):

In a 48-week trial, Retatrutide at higher doses (8-12mg) led to ~17-24% body weight loss in obese/overweight individuals.

The 1mg dose is likely a starting or lower-tier dose for gradual titration (similar to how other GLP-1 drugs are dosed).

Potential Benefits:

Significant weight loss (possibly surpassing tirzepatide and semaglutide).

Improved blood sugar control in type 2 diabetes.

Possible cardiovascular benefits (still under investigation).

Side Effects:

Similar to other GLP-1-based drugs: nausea, vomiting, diarrhea, constipation, and potential risk of pancreatitis or gallbladder issues.

Higher doses may have additional effects due to glucagon agonism (e.g., increased heart rate).

Availability:

Still in Phase 3 trials (expected completion ~2025-2026).

Not yet FDA-approved; commercial availability likely after 2026.

Comparison to Other Drugs:

Drug
Targets
Avg. Weight Loss
Stage of Development

Retatrutide
GIP, GLP-1, Glucagon
~17-24% (higher doses)
Phase 3 (2024)

Tirzepatide (Mounjaro/Zepbound)
GIP, GLP-1
~15-22%
FDA-approved (2022/2023)

Semaglutide (Wegovy/Ozempic)
GLP-1
~12-15%
FDA-approved (2017/2021)

Would You Like More Details On?

Dosing protocols for Retatrutide

Latest clinical trial updates

How it compares to Mounjaro/Wegovy

Let me know how I can refine the answer for your needs!